Thyroid Dysfunction: TSH Diagnostic Cascades, Free T4/T3, Hashimoto's, and Graves' Disease
Key Clinical Takeaways
- Thyroid-Stimulating Hormone (TSH) is the most sensitive primary screening test for assessing primary thyroid gland dysfunction.
- The hypothalamic-pituitary-thyroid negative feedback loop produces an inverse logarithmic relationship between TSH and circulating Free T4.
- Primary Hypothyroidism is confirmed by an elevated TSH (>4.5 mIU/L) with low Free T4; Hashimoto's thyroiditis is confirmed by Anti-TPO antibodies.
- Primary Hyperthyroidism is confirmed by a suppressed TSH (<0.4 mIU/L) with elevated Free T4/T3; Graves' disease is confirmed by Thyroid-Stimulating Immunoglobulin (TSI).
- Levothyroxine (synthetic T4) is dosed based on ideal body weight (1.6 mcg/kg/day), requiring strict administration on an empty stomach with water.
Emergency Clinical Warning
Thyroid Storm (extreme fever, tachycardia >140 bpm, delirium) and Myxedema Coma (severe hypothermia, bradycardia, lethargy) are life-threatening endocrine emergencies.
The Hypothalamic-Pituitary-Thyroid (HPT) Feedback Axis
Thyroid hormones—thyroxine (T4) and triiodothyronine (T3)—are critical iodinated amino acid derivatives that regulate basal metabolic rate, thermogenesis, cardiac contractility, protein synthesis, and lipid metabolism across virtually every human tissue. The synthesis and secretion of thyroid hormones are governed by an exquisite negative feedback neuroendocrine loop: 1. Hypothalamus: Releases Thyrotropin-Releasing Hormone (TRH). 2. Anterior Pituitary: TRH stimulates thyrotrope cells in the anterior pituitary to synthesize and release Thyroid-Stimulating Hormone (TSH, or thyrotropin). 3. Thyroid Gland: TSH binds to the G-protein coupled TSH receptor on thyroid follicular cells, stimulating every step of thyroid hormone production: iodide trapping, organification into thyroglobulin, coupling of monoiodotyrosine (MIT) and diiodotyrosine (DIT), and release of T4 (roughly 80-90%) and T3 (10-20%) into the circulation.
Crucially, the relationship between circulating Free T4 and pituitary TSH secretion is inverse and logarithmic: tiny physiological shifts in Free T4 concentrations produce immense, exponential reciprocal changes in serum TSH. Consequently, serum TSH serves as the definitive, ultra-sensitive primary screening biomarker for thyroid dysfunction.
The Diagnostic Reflex Algorithm: Primary vs. Subclinical Disorders
Clinical laboratory evaluation follows a standardized reflex algorithm initiated with a high-sensitivity third-generation TSH assay: - Elevated TSH (>4.5 mIU/L): Prompts automated reflex testing of Free T4: - High TSH + Low Free T4: Overt Primary Hypothyroidism. Manifests as lethargy, cold intolerance, weight gain, constipation, dry skin, bradycardia, and delayed deep tendon reflex relaxation. - High TSH + Normal Free T4: Subclinical Hypothyroidism. Treatment with levothyroxine is recommended if TSH >10 mIU/L, if symptomatic, if positive for anti-TPO antibodies, or in women planning pregnancy (where maternal T4 is vital for fetal neurodevelopment). - Suppressed TSH (<0.4 mIU/L, often <0.01): Prompts automated reflex testing of Free T4 and Free T3: - Low TSH + High Free T4/T3: Overt Primary Hyperthyroidism (Thyrotoxicosis). Manifests as heat intolerance, involuntary weight loss, resting tachycardia, fine tremors, diarrhea, and anxiety. - Low TSH + Normal Free T4/T3: Subclinical Hyperthyroidism. Evaluated for risk of osteoporosis and atrial fibrillation.
Autoantibody Differentiation: Hashimoto's vs. Graves' Disease
The vast majority of thyroid pathologies in iodine-sufficient North American populations are autoimmune in etiology: 1. Hashimoto's Thyroiditis (Chronic Autoimmune Thyroiditis): The leading cause of primary hypothyroidism in adults. Pathologically characterized by progressive lymphocytic infiltration, germinal center formation, and destruction of thyroid follicular architecture. Serological confirmation utilizes: - Anti-Thyroid Peroxidase (Anti-TPO) Antibodies: Present in >90% of Hashimoto's patients. - Anti-Thyroglobulin (Anti-Tg) Antibodies: Complementary diagnostic marker. 2. Graves' Disease: The leading cause of hyperthyroidism. Characterized by autoimmune humoral stimulation: - Thyroid-Stimulating Immunoglobulin (TSI / TRAb): Pathogenic autoantibodies that bind directly to and activate the TSH receptor, mimicking TSH and stimulating autonomous, unregulated thyroid hormone overproduction, accompanied by diffuse vascular goiter. TSI also binds to retro-orbital fibroblasts, driving Graves' Ophthalmopathy (proptosis, periorbital edema, diplopia). - Radioactive Iodine Uptake (RAIU): Demonstrates diffuse, high homogeneous thyroid gland uptake (typically 50-80%), distinguishing Graves' from subacute viral thyroiditis (which displays near-zero RAIU uptake during the destructive thyrotoxic release phase).
Levothyroxine Pharmacotherapy and Dosing Rules
Synthetic sodium levothyroxine (L-thyroxine; Synthroid, Tirosint) remains the evidence-based first-line replacement therapy for hypothyroidism. T4 acts as a prohormone: once absorbed, peripheral tissues enzymatically convert T4 into biologically active T3 via type 1 and type 2 iodothyronine deiodinases as physiologically required: - Initial Dosing: For healthy adults without cardiac disease, full replacement is calculated at 1.6 mcg/kg of ideal body weight per day (typically 75 to 125 mcg daily). In elderly patients or those with coronary artery disease, treatment initiates at low doses (25 to 50 mcg daily) to prevent unmasking angina or arrhythmias. - Administration Instructions: Levothyroxine has narrow absorption kinetics. It must be ingested strictly on an empty stomach with a full glass of water at least 30 to 60 minutes before breakfast, or at bedtime (at least 3 to 4 hours after the evening meal). - Absorption Interference: Co-administration with calcium carbonate, iron supplements, aluminum hydroxide antacids, soy products, or high-fiber meals physically binds levothyroxine in the gut, impairing absorption and driving TSH elevations. TSH is re-evaluated 6 to 8 weeks after any dose adjustment.
Thyroid Function Diagnostic Interpretation Matrix
| Serum TSH Level | Free T4 Level | Free T3 Level | Clinical Diagnosis | Initial Clinical Action |
|---|---|---|---|---|
| Elevated (> 4.5 mIU/L) | Low (< 0.8 ng/dL) | Low or Normal | Overt Primary Hypothyroidism | Initiate Levothyroxine (1.6 mcg/kg/day); check anti-TPO |
| Elevated (> 4.5 mIU/L) | Normal (0.8-1.8) | Normal | Subclinical Hypothyroidism | Treat if TSH >10, pregnant, or anti-TPO positive; otherwise monitor |
| Suppressed (< 0.1 mIU/L) | Elevated (> 1.8 ng/dL) | Elevated | Overt Primary Hyperthyroidism | Check TSI antibodies & RAIU scan; start Methimazole/Beta-blocker |
| Suppressed (< 0.1 mIU/L) | Normal | Elevated | T3 Toxicosis (Early Graves/Toxic Nodule) | Thyroid ultrasound, endocrinology referral |
| Suppressed (< 0.1 mIU/L) | Normal | Normal | Subclinical Hyperthyroidism | Screen for atrial fibrillation, DEXA scan, recheck in 3 mos |
| Low or Normal | Low (< 0.8 ng/dL) | Low | Secondary (Central / Pituitary) Hypothyroidism | Pituitary MRI, morning cortisol (DO NOT start T4 before cortisol) |
Frequently Asked Clinical Questions
Peer-Reviewed Clinical References & Guidelines
- Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract. 2012;18(6):988-1028.
- Kahaly GJ, Bartalena L, Hegedüs L, et al. 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism. Eur Thyroid J. 2018;7(4):167-186.
- Biondi B, Bartalena L, Cooper DS, et al. The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism. Eur Thyroid J. 2015;4(3):149-163.